Blood Cancers | Tumor

Stem Cell Transplant: Why This Treatment Is Still a ‘Standard Regimen’ for Blood Cancer

October 21st 2025, 3:56pm

Dr. Matthew Matasar discusses why stem cell transplant is still a standard, life-saving option in blood cancers and how CAR-T cell therapy is changing treatment decisions.

FDA Grants Fast Track to UB-VV111 for B-Cell Blood Cancers

October 8th 2025, 3:04pm

The FDA granted fast track status to UB-VV111 for patients with relapsed or refractory large B-cell lymphoma or chronic lymphocytic leukemia.

I No Longer Think About Cancer Every Day

September 30th 2025, 5:00pm

From The Leukemia and Lymphoma Society to Blood Cancer United

September 24th 2025, 9:00pm

CURE spoke with chief medical officer Gwen Nichols and partner Suleika Jaouad about the inclusive rebranding.

What Makes a Stem Cell Transplant Program Unique?

September 23rd 2025, 7:00pm

Dr. Christina Cho explains that a strong transplant program provides advanced treatments along with a supportive team for patients with blood cancers.

The Leukemia & Lymphoma Society is Now Blood Cancer United

September 23rd 2025, 3:12pm

The Leukemia & Lymphoma Society (LLS) is now Blood Cancer United.

Understanding Current Treatment for Myelofibrosis

September 23rd 2025, 1:00pm

Dr. Prithviraj Bose discussed the current treatment landscape for myeloproliferative neoplasms, a group of rare blood cancers; he focused on myelofibrosis.

What Does a Blood Cancer Diagnosis Mean?

September 5th 2025, 8:00pm

Your diagnosis of an early-stage blood cancer, such as a MPN or MDS, means that something has changed in the way your bone marrow produces blood cells.

Survivor Shares How Acupuncture and Nutrition Supported Treatment

August 13th 2025, 8:00pm

Follicular lymphoma survivor Troy Anderson credited acupuncture and nutrition guidance with easing treatment side effects and aided in remission.

New Guidelines Shift Donor Selection for Patients With Blood Cancer

August 11th 2025, 1:00pm

Advancements in transplant medicine for blood cancers have prompted updates in how doctors choose donors for allogeneic hematopoietic cell transplants.